Bioxytran is a public company focused on developing treatments for stroke and Ischemia. More than 140,000 deaths occur each year due to stroke. Sign up to learn more about BioxyTran and join the fight, because when it comes to stroke, every second counts.

PerfWeb Feature Presentation

Bioxytran Guest Speaker on Perfusionists Continuing Education Program Discusses Acute Respiratory Distress Syndrome and Ways to Combat COVID-19

Learn More

Introducing BXT-25

To learn more and become a part of the fight against stroke, sign up for our company newsletter for updates and more.

Join newsletter


With hypoxia, seconds make the difference between life and death. We are committed to bridging those moments through the structure of co-polymers. Based on Dr. David Platt's groundbreaking research in carbohydrate chemistry, Bioxytran, Inc is developing treatments for stroke and many other medical situations related to hypoxic conditions.

Learn More

Learn about Stroke
and Ischemia

In the United States, about 795,000 people suffer a stroke each year. Someone has a stroke every 40 seconds, and every 4 minutes someone dies from stroke. There are more than 140,000 deaths each year from stroke.  

Learn More


The key is BioXyTran's two workhorses: BXT-25 and BXT-252. Both drugs are designed to oxygenate ischemic (reduced blood flow) regions of the body and could provide sufferers valuable aid.

Learn More

Latest articles

Bioxtyran (OTCMKTS: BIXT) Licenses Phase 2 Asset for COVID-19 Patients After Finding Smoking Gun Journal Article
Mar 25, 2020

Bioxytran Inc. (OTCMKTS: BIXT) has a development stage hypoxia drug that that was initially targeting Acute Respiratory Distress Syndrome (ARDS) and stroke. Today they announced the licensing of a potentially phase 2 ready viral inhibitor which is designed to bind to a receptor on the protein spike of the virus.

BXT-25: A New Solution for Late Stage Treatment of Wuhan Coronavirus
Feb 13, 2020

Bioxytran Inc., a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a nanoscale oxygen carrier to affected tissues in the lungs, brain, heart, and other vital organs offers a new and possibly life-saving treatment option for late-stage 2019-nCoV.

Scientific Background How cells sense and adapt to oxygen availability
Nov 8, 2019

The Nobel Prize in Physiology or Medicine for 2019 is awarded to William Kaelin, Jr., Sir Peter Ratcliffe, and Gregg Semenza. The need for oxygen to sustain life has been understood since the onset of modern biology; but the molecular mechanisms underlying how cells adapt to variations in oxygen supply were unknown until the prize-winning work described here. Animal cells undergo fundamental shifts in gene expression when there are changes in the oxygen levels around them. 

see all

Lorem Ipsum

Ola Soderquist
Mr. Soderquist has more than 30 years of senior international entrepreneurial management experience within technology companies. He has served in CFO and other managerial capacities in multiple industry sectors and companies, such as Industrivarden (OMX:INDU), Electrolux (OMX:ELUX), Ericsson (NASDAQ:ERIC), Swedish Match (OMX:SWMA) and SKF AB (OMX:SKF), and most recently in Belden (NYSE: BDC) and Traction (OMX:TRAC).
Elena Chekhova
Chief Scientist
Elena Chekhova received her Ph.D in Process Systems Engineering at MIT; Elena has over 10 years of experience in the life sciences industry Most recently she founded Biotine Consulting, a life science consultancy providing business development and project management services to life science companies in the US and internationally.
David Platt
CEO & Chairman
Dr. Platt is a world-renowned expert in carbohydrate chemistry who has founded three publicly traded companies, creating nearly $1B for investors. He has raised $150M directly in public markets in the U.S., and has led development of two drug candidates from concept through phase II clinical trials.


Learn more about the team from BioxyTran


Learn more about BioxyTran investors and S1 Stocks


Join the conversation as we discuss Bioxytran's use-cases, development progress, and more.